Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant
Pharma
Priovant secures 1st FDA nod in rare skin and muscle disease
Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the FDA finish line, securing the asset its first nod in a rare skin disease.
Fraiser Kansteiner
Aug 27, 2026 9:30pm
Moderna commits $950M upfront to resolve patent lawsuit
Mar 4, 2026 10:33am
Amneal and VantAI unveil fresh branding to kick off 2026 plans
Jan 14, 2026 11:40am
Organon's Vtama, Galderma's Nemluvio endorsed by FDA for eczema
Dec 16, 2024 9:00am
Organon pays up to $1.2B to acquire Dermavant and its drug Vtama
Sep 18, 2024 10:09am
Dermavant's Vtama excels in another trial in atopic dermatitis
Jan 11, 2024 10:46am
